MCM

Preliminary effects of market correction mechanism on EU natural gas derivative market

Retrieved on: 
Friday, January 27, 2023
MCM, Place, Adoption, Medical device, EU

The report describes the structure and main participants in the EU natural gas derivative market and focuses on market indicators aimed at assessing the potential effects of the adoption of the MCM.

Key Points: 
  • The report describes the structure and main participants in the EU natural gas derivative market and focuses on market indicators aimed at assessing the potential effects of the adoption of the MCM.
  • -1
    Place
    Slide
    The report describes the structure and main participants in the EU natural gas derivative market and focuses on market indicators aimed at assessing the potential effects of the adoption of the MCM.

ESMA analyses preliminary effects of market correction mechanism on EU natural gas derivative market

Retrieved on: 
Friday, January 27, 2023
President of the European Council, Commission, European Securities and Markets Authority, Regulation (European Union), Agency, CCP, MCM, Adoption, Agency for the Cooperation of Energy Regulators, Risk management, Council of European Energy Regulators, ACER, European Council, Time, Medical device, Audit, ESMA, EU

ESMA analyses preliminary effects of market correction mechanism on EU natural gas derivative market

Key Points: 
  • ESMA analyses preliminary effects of market correction mechanism on EU natural gas derivative market
    The European Securities and Markets Authority, the EU’s financial markets regulator and supervisor, has today published its preliminary data report following the introduction of the market correction mechanism (MCM) in the EU Regulation.
  • The report describes the structure and main participants in the EU natural gas derivative market.
  • It focuses on market indicators aimed at assessing the potential effects of the adoption of the MCM.
  • Next steps
    Should stakeholders have any feedback on the preliminary data report, do not hesitate to reach out to ESMA.

IT market in Argentina 2023-2027: A descriptive analysis of five forces model, market dynamics, & segmentation- Technavio

Retrieved on: 
Wednesday, January 11, 2023
Government, Software, CAE, Health, Component, Projection, PCB, IDE, MCM, Public sector, Growth, UI, AI, IC, Insurance, BFSI, Mobile backend as a service, Analysis, IOT, Documentation, Marketing, Online shopping, Mobile phone, Medicine, Geography

The global IT market in Argentina is fragmented, and the five forces analysis covers–

Key Points: 
  • The global IT market in Argentina is fragmented, and the five forces analysis covers–
    Interpretation of porter's five models helps to strategize the business, for entire details – buy the report!
  • Technavio has segmented the market based on end-user (BFSI, IT and telecom, government, healthcare, and others), and type (services, software, and hardware).
  • The increasing adoption of cloud-based services is a key factor behind the growth of the Argentina information technology market.
  • The growing amount of data is notably driving the market growth, although factors such as adhering to diverse client requirements may impede the market growth.

Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

Retrieved on: 
Thursday, January 5, 2023
Government, U.S. Department of Defense Strategy for Operating in Cyberspace, Public health, CCC, RSDL, Emergent BioSolutions, Skin, United States Department of Defense, Canadian Commercial Corporation, MCM, T-2, NYSE, T-2 mycotoxin, EBS, Emergent, Pharmaceutical industry

GAITHERSBURG, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a maximum value up to $379.6 million to supply RSDL® (Reactive Skin Decontamination Lotion Kit) for use by all branches of the U.S. military.

Key Points: 
  • GAITHERSBURG, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a maximum value up to $379.6 million to supply RSDL® (Reactive Skin Decontamination Lotion Kit) for use by all branches of the U.S. military.
  • Emergent’s Canadian Subsidiary will serve as the sole subcontractor to deploy RSDL® to the U.S. Department of Defense (DoD) through a new contract award to the Canadian Commercial Corporation (CCC).
  • The new contract has a base year, which began in December 2022, and four single year option renewals.
  • RSDL has been procured for military and first responder use for over a decade and has been deployed in over 30 countries.

MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

Retrieved on: 
Thursday, December 29, 2022
Vericel, Office of Inspector General, U.S. Department of Health and Human Services, NEXT, TBSA, Administration, Cosmesis, Food, Burn, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ASPR, BLA, SOC, Regeneration, MCM, Trial of the century, Patient, Development, Eschar, HHS, Safety, Bromelain (pharmacology), FDA, Body surface area, Union, Incidence, Debridement, BARDA, Pharmaceutical industry

YAVNE, Israel, Dec. 29, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.

Key Points: 
  • “We are pleased and excited that the FDA has approved NexoBrid, an innovative, non-surgical alternative for the treatment of severe burn injuries,” said Ofer Gonen, Chief Executive Officer of MediWound.
  • We also thank our partner, BARDA, for their unwavering support since 2015, and our commercial partner, Vericel, who will launch NexoBrid in the U.S.
  • This U.S. FDA approval of NexoBrid validates our enzymatic technology platform.
  • MediWound will receive a $7.5 million milestone payment from Vericel Corporation, triggered by the FDA approval of NexoBrid.

Amerant Bancorp Names Erin Knight to its Board of Directors

Retrieved on: 
Monday, December 12, 2022
Trust, Stonegate Bank, LPO, Baptist Health, Knight, Regions Financial Corporation, Executive Committee, Bank, SouthTrust, Wells Fargo, Hope, MCM, Organization, CORAL, Home BancShares, Management, Financial services

CORAL GABLES, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Amerant Bancorp Inc. (NASDAQ: AMTB) (the “Company” or “Amerant”) and its subsidiary, Amerant Bank , the largest community bank headquartered in Florida, announced the appointment of Erin Knight to its Board of Directors, effective December 15, 2022.

Key Points: 
  • CORAL GABLES, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Amerant Bancorp Inc. (NASDAQ: AMTB) (the “Company” or “Amerant”) and its subsidiary, Amerant Bank , the largest community bank headquartered in Florida, announced the appointment of Erin Knight to its Board of Directors, effective December 15, 2022.
  • She is also on The Miami Foundation’s Board of Directors and is a Board and Executive Committee Member of the Baptist Health Foundation, among others.
  • “It is an honor to join Amerant’s Board of Directors,” said Knight.
  • (the “Bank”), as well as its other subsidiaries: Amerant Investments, Inc., Elant Bank and Trust Ltd., and Amerant Mortgage, LLC.

NextFlex Announces Over $8 Million in Funding for Flexible Hybrid Electronics Innovations in Advanced Semiconductor Packaging and Environmental Sustainability

Retrieved on: 
Monday, December 5, 2022
Other Manufacturing, Hardware, Electronic Design Automation, Packaging, Technology, Aerospace, Semiconductor, Manufacturing, CHIPS, Sentinel, Lockheed Martin Advanced Technology Laboratories, MCM, Auburn University, University, Defense, Thermal conductivity, UES, Laboratory, Doctor of Philosophy, FHE, United States Department of Defense, PCB, Research, Module, RF, General Dynamics Mission Systems, Sporting Arms and Ammunition Manufacturers' Institute, Silicon, Multi, Safety, Binghamton University, Temperature, Electronics, Raytheon Missiles & Defense, Television, Printed circuit board, Semiconductor

Project Call 7.0 also focuses on using hybrid electronics manufacturing processes and materials to improve environmental sustainability in electronics manufacturing.

Key Points: 
  • Project Call 7.0 also focuses on using hybrid electronics manufacturing processes and materials to improve environmental sustainability in electronics manufacturing.
  • This latest round of funding brings the total amount invested in FHE developments to more than $124M, including cost share contributions from Project Call participants.
  • The NextFlex member community is accelerating FHE and additively manufactured electronics toward commercialization in a number of critical application areas addressed in these projects.
  • Hybrid electronics are providing PCB and heterogeneous packaging manufacturers with novel additive electronics manufacturing solutions.

SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats

Retrieved on: 
Thursday, November 17, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tablet, Shanda, Mycosis, European Medicines Agency, WHO, Public health, Auris, Infection, Food, Biomedical Advanced Research and Development Authority, IC, EMA, IA, Biotechnology, BAA, Candida auris, Patient, QIDP, Candidiasis, Broad Agency Announcement, Aspergillus fumigatus, FURI, World Health Organization, Mucorales, News, BID, Fungemia, Fungus, Development, CBRN, Canker, IV, Drug of last resort, New Drug Application, MCM, PDUFA, FDA, Antibiotics, Pharmaceutical industry

For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.

Key Points: 
  • For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.
  • It is extremely exciting to see BARDA announce increased emphasis on fighting dangerous fungal pathogens, said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS.
  • Ibrexafungerp, with its promising activity against multiple drug resistant and often-deadly fungal infections, has enormous potential to benefit patients with severe fungal disease and limited treatment options.
  • In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

Inter Parfums, Inc. Announces Initial 2023 Guidance

Retrieved on: 
Monday, November 21, 2022
Fashion, Cosmetics, Retail, Luxury, Other Retail, Specialty, Boucheron, Hollister, Advertising, Kate Spade, MCM, Abercrombie, Abercrombie & Fitch, GUESS, DKNY, News, Montblanc, Annual report, Ungaro, Oscar de la Renta, Van Cleef & Arpels, Nature, Form 10-K, Security (finance), Risk, Growth, COVID-19, Cosmetics, Lanvin

Inter Parfums, Inc. (NASDAQ GS: IPAR) today announced that it expects 2023 net sales of $1.11 billion, resulting in earnings per diluted share of $3.70.

Key Points: 
  • Inter Parfums, Inc. (NASDAQ GS: IPAR) today announced that it expects 2023 net sales of $1.11 billion, resulting in earnings per diluted share of $3.70.
  • Guidance assumes that the average dollar/euro exchange rate remains at current levels and there is no significant resurgence of the COVID-19 pandemic.
  • Jean Madar, Chairman & Chief Executive Officer of Inter Parfums, Inc. noted, Building upon the record sales we are projecting in 2022, the increase in 2023 that we anticipate is due to a number of factors.
  • Inter Parfums does not intend to and undertakes no duty to update the information contained in this press release.

Global Biodefense Market Report to 2030 - Featuring Altimmune, Emergent BioSolutions, SIGA Technologies and Ichor Medical Systems Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, November 21, 2022
Biotechnology, Pharmaceutical, Health, Horizon, Prevalence, Incidence, European Commission, Operation Warp Speed, Plant, Zika virus, Public–private partnership, MCM, Merck, Bacteria, Office of Inspector General, U.S. Department of Health and Human Services, Framework Programmes for Research and Technological Development, Partnership, Infection, Bioterrorism, Government, Animal, National Healthcare Group, Korea Disease Control and Prevention Agency, CDC, Virus, Crimean–Congo hemorrhagic fever, Vaccination, Death, Human, USD, Military personnel, Research, Disease, Mortality, Fungus, Therapy, COVID-19 vaccine, Fever Dream, HHS, COVID-19, CCHF, Merck & Co., NHC, Vaccine, Pharmaceutical industry

The pandemic has also highlighted the importance of investing in strong biodefense infrastructure, which is expected to drive market growth over the forecast period.

Key Points: 
  • The pandemic has also highlighted the importance of investing in strong biodefense infrastructure, which is expected to drive market growth over the forecast period.
  • Biodefense comprises medical countermeasures (MCM) and other actions taken to protect people from the effects of biological warfare agents or bioterrorism.
  • The global biodefense market is expected to grow at a CAGR of over 12% during the period of 2021-2031.
  • For this report, the author has segmented the global biodefense market based on product type, application, end-use, and region: